Discovery of BRM targeted therapies: Novel reactivation of an anticancer gene

Letters in Drug Design and Discovery

Volumn 8, Issue 1, 2011, Pages 93-99

  Gramling, S ^a   Reisma, D ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Anticancer; Brahma; High throughput screening; SWI SNF; Tumor suppressor Epigenetic suppression

Indexed keywords

BRM PROTEIN; BUTYRIC ACID; DEXAMETHASONE; ENTINOSTAT; FLAVONE DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; INDOPROFEN; METHOXYFLAVONE; PROTEIN SWI; TACEDINALINE; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANTITUMOR GENE; ARTICLE; CANCER INHIBITION; DNA POLYMORPHISM; DRUG RESEARCH; GENE EXPRESSION; GENE LOSS; GENE SILENCING; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR SUPPRESSOR GENE;

EID: 78650873442     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018011793663840     Document Type: Article

References (34)

1. Reisman, D.; Glaros, S.; Thompson, E.A. The SWI/SNF complex and cancer. Oncogene, 2009, 28(14), 1653-1668.
2. Glaros, S.; Cirrincione, G.M.; Muchardt, C.; Kleer, C.G.; Michael, C.W.; Reisman, D. The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Oncogene, 2007, 26(49), 7058-7066.
3. Yamamichi, N.; Yamamichi-Nishina, M.; Mizutani, T.; Watanabe, H.; Minoguchi, S.; Kobayashi, N.; Kimura, S.; Ito, T.; Yahagi, N.; Ichinose, M.; Omata, M.; Iba, H. The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential. Oncogene, 2005, 24(35), 5471-5481.
4. Bourachot, B.; Yaniv, M.; Muchardt, C. Growth inhibition by the mammalian SWI-SNF subunit Brm is regulated by acetylation. EMBO J., 2003, 22(24), 6505-6515.
5. Oh, J.; Sohn, D.H.; Ko, M.; Chung, H.; Jeon, S.H.; Seong, R.H. BAF60a interacts with p53 to recruit the SWI/SNF complex. J. Biol. Chem., 2008, 283(18), 11924-11934.
6. Naidu, S.R.; Love, I.M.; Imbalzano, A.N.; Grossman, S.R.; Androphy, E.J. The SWI/SNF chromatin remodeling subunit BRG1 is a critical regulator of p53 necessary for proliferation of malignant cells. Oncogene, 2009, 28(27), 2492-2501.
7. Lee, J.H.; Lee, J.Y.; Chang, S.H.; Kang, M.J.; Kwon, H. Effects of Ser2 and Tyr6 mutants of BAF53 on cell growth and p53- dependent transcription. Mol. Cells, 2005, 19(2), 289-293.
8. Lee, D.; Kim, J.W.; Seo, T.; Hwang, S.G.; Choi, E.J.; Choe, J. SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. J. Biol. Chem., 2002, 277(25), 22330-22337.
9. Zhang, H.S.; Gavin, M.; Dahiya, A.; Postigo, A.A.; Ma, D.; Luo, R.X.; Harbour, J.W.; Dean, D.C. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDACRb- hSWI/SNF and Rb-hSWI/SNF. Cell, 2000, 101(1), 79-89.
10. Strobeck, M.W.; Knudsen, K.E.; Fribourg, A.F.; DeCristofaro, M.F.; Weissman, B.E.; Imbalzano, A.N.; Knudsen, E.S. BRG-1 is required for RB-mediated cell cycle arrest. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(14), 7748-7753.
11. Reisman, D.N.; Strobeck, M.W.; Betz, B.L.; Sciariotta, J.; Funkhouser, W., Jr.; Murchardt, C.; Yaniv, M.; Sherman, L.S.; Knudsen, E.S.; Weissman, B.E. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene, 2002, 21(8), 1196-1207.
12. Strober, B.E.; Dunaief, J.L.; Guha; Goff, S.P. Functional interactions between the hBRM/hBRG1 transcriptional activators and the pRB family of proteins. Mol. Cell Biol., 1996, 16(4), 1576-1583.
13. Dunaief, J.L.; Strober, B.E.; Guha, S.; Khavari, P.A.; Alin, K.; Luban, J.; Begemann, M.; Crabtree, G.R.; Goff, S.P. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell, 1994, 79(1), 119-130.
14. Park, J.H.; Park, E.J.; Lee, H.S.; Kim, S.J.; Hur, S.K.; Imbalzano, A.N.; Kwon, J. Mammalian SWI/SNF complexes facilitate DNA double-strand break repair by promoting gamma-H2AX induction. EMBO J., 2006, 25(17), 3986-3997.
15. Park, J.H.; Park, E.J.; Hur, S.K.; Kim, S.; Kwon, J. Mammalian SWI/SNF chromatin remodeling complexes are required to prevent apoptosis after DNA damage. DNA Repair (Amst), 2009, 8(1), 29-39.
16. Gong, F.; Fahy, D.; Liu, H.; Wang, W.; Smerdon, M.J. Role of the mammalian SWI/SNF chromatin remodeling complex in the cellular response to UV damage. Cell Cycle, 2008, 7(8), 1067-1074.
17. Batsche, E.; Yaniv, M.; Muchardt, C. The human SWI/SNF subunit Brm is a regulator of alternative splicing. Nat. Struct. Mol. Biol., 2006, 13(1), 22-29.
18. Strobeck, M.W.; DeCristofaro, M.F.; Banine, F.; Weissman, B.E.; Sherman, L.S.; Knudsen, E.S. The BRG-1 subunit of the SWI/SNF complex regulates CD44 expression. J. Biol. Chem., 2001, 276(12), 9273-9278.
19. Zraly, C.B.; Middleton, F.A.; Dingwall, A.K. Hormone-response genes are direct in vivo regulatory targets of Brahma (SWI/SNF) complex function. J. Biol. Chem., 2006, 281(46), 35305-35315.
20. Sudarsanam, P.; Iyer, V.R.; Brown, P.O.; Winston, F. Wholegenome expression analysis of snf/swi mutants of Saccharomyces cerevisiae. Proc. Natl. Acad Sci. U.S. A., 2000, 97(7), 3364-3369.
21. Kim, C.F.; Jackson, E.L.; Kirsch, D.G.; Grimm, J.; Shaw, A.T.; Lane, K.; Kissil, J.; Olive, K.P.; Sweet-Cordero, A.; Weissleder, R.; Jacks, T. Mouse models of human non-small-cell lung cancer raising the bar. Cold Spring Harb Symp. Quant. Biol., 2005, 70, 241-250.
22. Jacks, T. Lessons from the p53 mutant mouse. J. Cancer Res. Clin. Oncol., 1996, 122(6), 319-327.
23. Reyes, J.C.; Barra, J.; Muchardt, C.; Camus, A.; Babinet, C.; Yaniv, M. Altered control of cellular proliferation in the absence of mammalian brahma (SNF2alpha). EMBO J., 1998, 17(23), 6979-6991.
24. Liu, G.; Rogers, C.B.; Munoz, D.; Gordon, V.; Cheng, D.; Kalam,A.; Mirshams, M.; Xu, W.; Shepherd, F.; Tsao, M.; Reisman, D.Two novel functional BRM insertion promoter polymorphisms, loss of BRM expression, and lung cancer risk. Oncogene, 2010, Submitted.
25. Fickett, J.W. Quantitative discrimination of MEF2 sites. Mol. Cell Biol., 1996, 16(1), 437-441.
26. Nebbioso, A.; Manzo, F.; Miceli, M.; Conte, M.; Manente, L.; Baldi, A.; De Luca, A.; Rotili, D.; Valente, S.; Mai, A.; Usiello, A.; Gronemeyer, H.; Altucci, L. Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep., 2009, 10(7), 776-782.
27. Gregoire, S.; Xiao, L.; Nie, J.; Zhang, X.; Xu, M.; Li, J.; Wong, J.; Seto, E.; Yang, X.J. Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol. Cell Biol., 2007, 27(4), 1280-1295.
28. Bertos, N.R.; Wang, A.H.; Yang, X.J. Class II histone deacetylases: structure, function, and regulation. Biochem. Cell Biol., 2001, 79(3), 243-252.
29. Inoue, H.; Furukawa, T.; Giannakopoulos, S.; Zhou, S.; King, D.S.; Tanese, N. Largest subunits of the human SWI/SNF chromatinremodeling complex promote transcriptional activation by steroid hormone receptors. J. Biol. Chem., 2002, 277(44), 41674-41685.
30. Fryer, C.J.; Archer, T.K. Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex. Nature, 1998, 393(6680), 88-91.
31. Hsiao, P.W.; Fryer, C.J.; Trotter, K.W.; Wang, W.; Archer, T.K. BAF60a mediates critical interactions between nuclear receptors and the BRG1 chromatin-remodeling complex for transactivation. Mol. Cell Biol., 2003, 23(17), 6210-6220.
32. Zhang, J.H.; Chung, T.D.; Oldenburg, K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen, 1999, 4(2), 67-73.
33. Cheadle, C.; Vawter, M.P.; Freed, W.J.; Becker, K.G. Analysis of microarray data using Z score transformation. J. Mol. Diagn., 2003, 5(2), 73-81.
34. Rabow, A.A.; Shoemaker, R.H.; Sausville, E.A.; Covell, D.G. Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. J. Med. Chem., 2002, 45(4), 818-840.